XII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Welcome and introduction 8.45-8.50

 

Session 1 Prognostic markers and risk stratification 08.50-11.00
Chaired by Hartmut Döhner

Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays
Hendrik Veelken

CpG oligonucleotide-induced metaphase cytogenetics: identification of novel abnormalities in CLL
Claudia Haferlach

Biological markers: data from the LRF CLL4 trial
David Oscier

Oral poster presentations

 

Session 2 Mechanism of disease 11.30-13.15
Chaired by Federico Caligaris-Cappio

CLL: at the intersection of autoimmunity, innate and adaptive immunity, and malignancy
Nicholas Chiorazzi

Immunoglobulin receptors in CLL: a bridge between microenvironment and intracellular activation
Paolo Ghia
New insights into the pathogenesis of CLL by in vitro and in vivo models
Riccardo Dalla-Favera
Oral poster presentation

 

Session 3 Molecular genetics 14.30-17.00
Chaired by Thomas Kipps

Micro RNAs in leukemogenesis (Leukaemia Research Fund lecture)
Carlo Croce

Predisposition genes in CLL
Richard Houlston

Oral poster presentations

Poster viewing

 

Welcome reception 18.00-19.30

Session 4 Clinical application of laboratory methods 08.45-11.00
Chaired by Peter Hillmen

The assessment of MRD in CLL and its clinical significance
Andy Rawstron

Assessment of ZAP70 and other prognostic factors
Florence Cymbalista

Memorial to David Galton
Daniel Catovsky, Kanti Rai and Gerald Marti

Presentation of Rai/Binet medals

Oral poster presentations

 

Session 5 New agents 11.30-13.15
Chaired by Michael J Keating

Flavopiridol: past the checkpoint
John Byrd

CLL B cell-stromal interaction: opportunities for therapy
Neil Kay

Purine analogs: not dead yet
William Plunkett

Oral poster presentation

  

Session 6 Immunotherapy 14.30-16.40
Chaired by Michael Hallek

Progress in gene therapy
William Wierda

Alemtuzumab in CLL: current status and future prospects
Anders Osterborg

Antibodies against B cells and their role in the management of CLL
Bruce Cheson

CLL therapy in elderly patients: quality of life and outcome
Barbara Eichhorst

Oral poster presentation
 

Additional poster viewing time

Session 7 The role of stem cell transplantation: risks and benefits 08.45-12.00
Chaired by Emili Montserrat

Stem cell transplants in CLL: when and how
Peter Dreger

Prognostic factors in patients with CLL who have received a stem cell transplant
John Gribben

Chemotherapy vs autotransplantation in CLL
Laurent Sutton

MRD in CLL transplants: clinical significance and background for improving transplants
Carol Moreno

Are RIC allogeneic stem cell transplants ready for prime time in CLL therapy?
Rainer Storb